MCL1 and acute myeloid leukemia: Single-cell DNA sequencing demonstrated clonal selection of RAS-mutated clones in AML patients treated with VEN-containing regimens, and combined VEN with MCL-1 inhibitor exhibited superior anti-leukemia effect in MOLM-13 gain-of-function NRAS-G12D mutation in vitro and mouse model in vivo, supporting the future need to co-target this signaling axis to improve the longevity of responses.